Subject assessment (RAST positive ITT§) | Ketotifen (n = 109) | 49.5 | | |
| Placebo (n = 106) | 33.0 | 1.99 | 0.02 |
| Levocabastine (n = 107) | 41.1 | 1.43 | 0.20 |
Investigator assessment (RAST positive ITT§) | Ketotifen (n = 109) | 53.2 | | |
| Placebo (n = 106) | 32.1 | 2.49 | 0.001 |
| Levocabastine (n = 107) | 45.8 | 1.39 | 0.24 |
Subject assessment (ITT) | Ketotifen (n = 163) | 47.9 | | |
| Placebo (n = 165) | 39.4 | 1.41 | 0.13 |
| Levocabastine (n = 166) | 38.6 | 1.46 | 0.09 |
Investigator assessment (ITT) | Ketotifen (n = 163) | 50.3 | | |
| Placebo (n = 165) | 38.2 | 1.66 | 0.02 |
| Levocabastine (n = 166) | 41.0 | 1.45 | 0.09 |
Subject assessment (PP) | Ketotifen (n = 85) | 50.6 | | |
| Placebo (n = 78) | 35.9 | | |
| Levocabastine (n = 75) | 41.3 | 1.83 | 0.06 |
Investigator assessment (PP) | Ketotifen (n = 85) | 56.5 | 1.48 | 0.30 |
| Placebo (n = 78) | 34.6 | 2.51 | 0.005 |
| Levocabastine (n = 75) | 46.7 | 1.58 | 0.16 |